In the study subjects received either a single dose of the ingredient at 250 mg or 500 mg, or an 1800 mg dose of a standard 95% turmeric extract
OmniActive Health Technologies has highlighted recent research, published in Advances in Therapy, on the bioavailability of its Curcuwin Ultra+ ingredient. The study will also be presented during the annual Experimental Biology meeting in Philadelphia, PA, in April.
In the randomised, double-blind, three treatment, crossover oral bioavailability study involving 24 healthy male and female volunteers between 18 and 55, subjects received either a single dose of the ingredient at 250 mg or 500 mg, or an 1800 mg dose of a standard 95% turmeric extract.
According to the study, the 250 mg dose of OmniActive’s ingredient was 144 times more bioavailable than the standard curcumin, and was also shown to absorb 40% faster.
The ingredient was developed with the aim of bringing a lower dose curcumin supplement to support joint and general health in individuals with active lifestyles.
“OmniActive continues to champion innovation and invest in science for the betterment of human nutrition,” said Deshanie Rai, PhD, VP, Global Scientific and Regulatory Affairs, OmniActive. “Having our data selected to be presented at the prestigious EB meeting and accepted for publication in the well-respected peer reviewed journal, Advances in Therapy, speaks to the strength and relevance of this new science.”